LH

Laboratory
D

LH

Arincen56/100B

Laboratory return on equity (ROE)

Laboratory's return on equity is 11.36%: net income of 1.01B USD over the last twelve months on shareholders' equity of 8.85B USD.

Today
11.36%
Average, 5 years
11.10%
Low, 5 years
5.25%
High, 5 years
23.16%

ROE (return on equity) = net income (last 12 months) ÷ shareholders' equity = 1.01B ÷ 8.85B = 11.36%

ROE (return on equity)
Net income
Shareholders' equity

Each quarter's net income over its last four quarters, over the shareholders' equity at the quarter end.

What drives Laboratory's return on equity?

Net margin
6.3%
profit on each dollar of sales
Asset turnover
0.76×
sales on each dollar of assets
Equity multiplier
2.13×
assets on each dollar of equity
Return on equity
10.2%
FY2025
  • FY20256.3% × 0.76 × 2.13 = 10.2%
  • FY20245.7% × 0.71 × 2.28 = 9.3%
  • FY20233.4% × 0.73 × 2.12 = 5.3%
  • FY202210.8% × 0.59 × 2.00 = 12.7%
  • FY202118.1% × 0.64 × 1.98 = 23.1%

The DuPont breakdown, on each year-end's assets and equity, as the return on equity elsewhere on this page. A high equity multiplier means a small equity base: debt, or buybacks that return the equity to shareholders, lift the return on what is left.

ROE (return on equity) by year and by quarter

Fiscal yearPeriod endingROE (return on equity)Net incomeShareholders' equity
Today11.36%1.01B8.85B
FY202531 Dec 202510.18%877.70M8.62B
FY202431 Dec 20249.26%746.00M8.05B
FY202331 Dec 20234.82%379.20M7.88B
FY202231 Dec 20229.94%1.00B10.10B
FY202131 Dec 202123.16%2.38B10.27B
FY202031 Dec 202016.50%1.56B9.44B
FY201931 Dec 201910.90%824.90M7.57B
FY201831 Dec 201812.68%883.90M6.97B
FY201731 Dec 201718.72%1.27B6.80B
FY201631 Dec 201613.32%733.20M5.51B
FY201531 Dec 20158.86%438.00M4.95B
FY201431 Dec 201418.17%512.60M2.82B
FY201331 Dec 201323.10%575.40M2.49B
FY201231 Dec 201221.52%584.80M2.72B
FY201131 Dec 201121.29%533.10M2.50B
FY201031 Dec 201023.18%571.60M2.47B
FY200931 Dec 200926.38%555.60M2.11B
FY200831 Dec 200827.51%464.50M1.69B
FY200731 Dec 200727.64%476.80M1.73B
FY200631 Dec 200621.83%431.60M1.98B
FY200531 Dec 200520.48%386.20M1.89B
FY200431 Dec 200418.16%363.00M2.00B
FY200331 Dec 200316.93%321.00M1.90B
FY200231 Dec 200215.80%254.60M1.61B
FY200131 Dec 200116.54%179.50M1.09B
FY200031 Dec 200012.78%112.10M877.40M
FY199931 Dec 19998.91%65.40M734.20M
FY199831 Dec 199810.10%68.80M681.20M
FY199731 Dec 1997-16.97%-106.90M630.00M
FY199631 Dec 1996-59.47%-153.50M258.10M
FY199531 Dec 1995-0.97%-4.00M411.60M
FY199431 Dec 199418.13%30.10M166.00M
FY199331 Dec 199380.04%112.70M140.80M
FY199231 Dec 199219.11%40.60M212.50M
FY199131 Dec 199131.41%103.90M330.80M
FY199031 Dec 199032.18%82.60M256.70M
FY198931 Dec 198919.61%64.70M330.00M
FY198831 Dec 1988—49.10M—

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,Current ratio,All ratios

Common questions about Laboratory's ROE

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.